January 25, 2018 / 9:20 AM / 8 months ago

BRIEF-Gensight Biologics Reports 55 Million Euros 2017 Year-End Cash Position

Jan 25 (Reuters) - GENSIGHT BIOLOGICS SA:

* GENSIGHT BIOLOGICS REPORTS €55 MILLION 2017 YEAR-END CASH POSITION AND PROVIDES CORPORATE UPDATE

* TOPLINE RESULTS OF REVERSE AND RESCUE ARE EXPECTED IN APRIL AND 3Q 2018, RESPECTIVELY.

* REFLECT, PHASE III CLINICAL TRIAL: FIRST PATIENT IS EXPECTED TO BE TREATED IN 1Q 2018 IN US.

* PIONEER PHASE I/II CLINICAL TRIAL: FIRST PATIENT IS EXPECTED TO BE TREATED IN 1Q 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below